

REMARKS

Correction of Sequence Listing

The "Notice to Comply With Requirements For Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures (hereinafter "the Notice") of July 2, 2004 to which this Amendment responds stated although a copy of the Sequence Listing in computer readable form was submitted, the content of the computer readable form does not allegedly comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the Raw Sequence Listing Error Report. The Notice stated that Applicants must provide a substitute computer readable form copy of the Sequence Listing and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and includes no new matter as required by 37 C.F.R. Section 1.821(e-g) and 1.825(b) and 1.825(d).

In response Applicants are filing herewith a substitute Sequence Listing for the nucleotide/amino acid sequence(s) in this application and 3.5 inch labeled diskette having thereon a substitute computer readable form copy of the substitute Sequence Listing. The attached diskette is labeled in accordance with 37 C.F.R. 1.824(a)(6) and is submitted in the American Standard Code for Information Interchange (ASCII) text.

Herein below is the requested statement that the content of the sequence listing information recorded in computer readable form is identical to the written sequence listing as required by 37 C.F.R. Section 1.821(g). Because this submission is made in fulfilling the requirement under 37 C.F.R. 1.821(g), also included herein below is a statement that the submission includes no new matter.

Statement that Sequence Listing and Computer Readable Copy Thereof Are the Same And That Papers Submitted Includes No New Matter

I, Raymond J. Harmuth, Esq., Registration No. 33,896 hereby state:

1. That I am a registered patent attorney employed by the assignee of the present application and am empowered to act in this case;


2. That the substitute computer readable form being submitted concurrently herewith is identical to the written substitute Sequence Listing also being submitted concurrently herewith;

3. That the amendments made in the substitute sheets of the Sequence Listing are supported in the application, as filed, and that the substitute sheets of the Sequence Listing do not include new matter.

Having complied with all of the outstanding requirements, Applicants request that the file be forwarded for examination.

Respectfully submitted,

By



Raymond J. Harmuth
Attorney for Applicants
Reg. No. 33,896

Bayer CropScience LP
100 Bayer Road
Pittsburgh, Pennsylvania 15205-9741
(412) 777-3916
FACSIMILE PHONE NUMBER:
(412) 777-3902
s/rmc/rjh/0303